Risks and benefits of structured antiretroviral drug therapy interruptions in HIV-1 infection

AIDS

Volumn 14, Issue 15, 2000, Pages 2313-2322

  Bonhoeffer, S ^a   Rembiszewski, M ^a   Ortiz, G M ^a   Nixon, D F ^a  

^a FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH   (Switzerland)

Author keywords

Cytotoxic T lymphocytes; Drug resistance; HIV dynamics; Latent cell compartment; Mathematical model; Structured therapy interruption; Virus control

Indexed keywords

ANTIRETROVIRUS AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL COMPARTMENTALIZATION; DRUG EFFECT; DRUG WITHDRAWAL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; MATHEMATICAL MODEL; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TARGET CELL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MICROBIAL; HIV INFECTIONS; HIV-1; HUMANS; MODELS, THEORETICAL; RISK ASSESSMENT; T-LYMPHOCYTES, CYTOTOXIC; VIRUS LATENCY;

EID: 0033768519     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200010200-00012     Document Type: Article

References (43)

1. Latent infection of CD4(+) T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
2. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
3. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with infection
4. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
5. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques
6. Cytotoxic T lymphocytes specific for the simian immunodeficiency virus
7. Can immune systems be trained to fight HIV
8. Control of HIV despite the discontinuation of antiretroviral therapy
9. HIV-1-specific immune responses in subjects who temporarily contain antiretroviral therapy
10. Strong HlV-1-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
11. Boosting of HIV-1 specific cellular immune responses in chronically infected persons following treatment interruptions
12. Longitudinal and cross-sectional analysis of cytotoxic T lymphocyte responses and their relationship to vertical human immunodeficiency virus transmission
13. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection
14. Viral dynamics in human immunodeficiency virus type 1 infection
15. Virus dynamics and drug treatment
16. Population dynamics of immune responses to persistent viruses
17. HIV-drug therapy and virus load
18. Target cell limited and immune control models of HIV infection: A comparison
19. Evolutionary dynamics of HIV-induced subversion of the immune response
20. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease
21. Potent antiretroviral therapy of primary human immunodeficiency type 1 (HIV-1) infection: Partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia
22. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
23. Cytotoxic T lymphocytes and viral turnover in HIV type 1 infection
24. Specific therapy regimens could lead to long-term immunological control of HIV
25. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques
26. Temporal association of cellular immune-responses with the initial control of viremia in primary human-immunodeficiency-virus type-1 syndrome
27. A recombinant vaccinia virus based elispot assay detects high frequencies of pol-specific CD8 T cells in HIV-1-positive
28. Phenotypic analysis of antigen-specific T lymphocytes
29. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy
30. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
31. HIV-1-specific CD4(+) T cells are detectable in most individuals active HIV-1 infection, but decline with prolonged viral suppression
32. Molecular tracking of an human immunodeficiency virus specific cytotoxic T-cell clone shows persistence of clone-specific T-cell receptor DNA but not mRNA following early combination antiretroviral therapy
33. Evaluating treatment protocols to prevent or delay the emergence of antibiotic resistance
34. Pre-existence and the emergence of drug resistance in HIV-infection
35. Production of resistant HIV mutants during antiretroviral therapy
36. A stochastic model for primary HIV infection: Optimal timing of therapy
37. The frequency of drug resistant mutants before therapy
38. Anti-viral drug treatment: Dynamics of resistance in free virus and infected cell populations
39. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
40. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time
41. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques
42. Rapid production and clearance of HIV-1 and hepatitis
43. Models of viral kinetics and drug resistance in HIV-1 infection